Ignite Creation Date:
2024-05-06 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 1:55 PM
Study NCT ID:
NCT04733430
Status:
RECRUITING
Last Update Posted:
2024-03-18
First Post:
2021-01-18
Brief Title:
LALUCA Research Platform A Prospective Analysis of Lung Cancer Diagnosis and Management in Clinical Practice
Sponsor:
Karl Landsteiner Institute for Lung Research and Pneumological Oncology
Organization:
Karl Landsteiner Institute for Lung Research and Pneumological Oncology
Study Overview
Official Title:
Landsteiner Lung Cancer Research Platform LALUCA A Prospective Analysis of Lung Cancer Diagnosis and Management in Clinical Practice
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LALUCA
Brief Summary:
This is a prospective analysis of the diagnosis and treatment of lung cancer in a real-world setting The aim of the project is to establish a clinical platform to collect representative data on molecular testing sequence of systemic tumor therapy and other therapies and disease progression of patients with lung cancer A special focus will be on molecular biomarker testing and reflex NGS testing Another aim of the registry is the collection of quality indicators in lung cancer care The results of the register will be used to describe the current state of care and to develop it further for the future
Detailed Description:
The identification of driver-mutations whose gene product can be specifically inhibited by targeted therapies has markedly changed the diagnostic and therapeutic landscape for this tumor entity leading to improved outcomes for patients with metastatic NSCLC
The use of next generation sequencing NGS allows for detection of a multitude of different druggable mutations In absence of a curative treatment approach and a druggable mutation the prognosis of lung cancer remains poor
Thorough knowledge of the treatment reality eg characteristics diagnostic treatment and outcome of unselected patients in real-Iife practice is crucial to evaluate and improve the quality of care for patients with lung cancer
The purpose of this project is to set up a clinical platform to document representative data on molecular testing sequence of systemic treatment and other treatment modalities and course of disease in patients with lung cancer A particular focus is on molecular biomarker testing and NGS of patients before the start of first-line treatment The data shall be used to assess the current state of care and to develop recommendations concerning topics that can be improved
The use of next generation sequencing NGS allows for detection of a multitude of different druggable mutations In absence of a curative treatment approach and a druggable mutation the prognosis of lung cancer remains poor
Thorough knowledge of the treatment reality eg characteristics diagnostic treatment and outcome of unselected patients in real-Iife practice is crucial to evaluate and improve the quality of care for patients with lung cancer
The purpose of this project is to set up a clinical platform to document representative data on molecular testing sequence of systemic treatment and other treatment modalities and course of disease in patients with lung cancer A particular focus is on molecular biomarker testing and NGS of patients before the start of first-line treatment The data shall be used to assess the current state of care and to develop recommendations concerning topics that can be improved
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None